Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL [Seeking Alpha]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Seeking Alpha
Summary Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early trials, more than double the current standard of care. The PTCL market, estimated at $500 million in the U.S., offers significant potential if Soquelitinib's Phase 3 trials are successful. CRVS's financials reveal a somewhat tight cash runway of 2.1 years, but favorable trial data could boost investor optimism and support the stock price. I deem CRVS a speculative "buy" due to its early-stage IP and inherently long-term investment thesis. Morsa Images Corvus Pharmaceuticals, Inc. ( NASDAQ: CRVS ) is a clinical-stage biotech focused on innovative cancer and immune disease treatments. Its IP leverages targeted small molecules and antibodies. Currently, its leading program is an ITK inhibitor called Soquelitinib, which is indicated for T-cell lymphomas like PTCL. So fa
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic SclerosisGlobeNewswire
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $8.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
- Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... [Yahoo! Finance]Yahoo! Finance
CRVS
Earnings
- 11/12/24 - Miss
CRVS
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 10/23/24 - Form 8-K
- CRVS's page on the SEC website